{"id":1018378,"date":"2026-11-06T09:19:12","date_gmt":"2026-11-06T14:19:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/"},"modified":"2026-11-06T09:19:12","modified_gmt":"2026-11-06T14:19:12","slug":"hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/","title":{"rendered":"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting"},"content":{"rendered":"
\n

\n HCW11-018b induces\/promotes tertiary lymphoid structure formation inside tumors<\/em>\n <\/p>\n

\n HCW11-018b converts immunological \u201ccold\u201d tumors into \u201chot\u201d tumors<\/em>\n <\/p>\n

\n HCW11-018b was generated using the Company\u2019s non-Fc TRBC platform, combining elements that enhance T-cell activation and tumor infiltration while mitigating immunosuppression<\/em>\n <\/p>\n

MIRAMAR, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) — — HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and leading developer in novel multi-functional fusion immunotherapeutics, for the treatment of autoimmune diseases, cancer, and senescence-associated dysplasia, announced a major update for its multivalent, second-generation T-Cell Engager (\u201cTCE\u201d) Program, presented at the 41st<\/sup> Annual Meeting of the Society for Immunotherapy of Cancer (\u201cSITC\u201d), taking place from November 4 \u2013 8, 2026, in Phoenix, Arizona.<\/p>\n

The Poster (Abstract #627), entitled, \u201cAn innovative approach to improve Bispecific T-cell engagers for solid tumor therapy<\/em>,\u201d will be presented during the Poster Session at Poster Hall from 10 a.m.\u2013 2 p.m. MT and 5 \u2013 7 p.m. MT, on Friday, November 6.<\/p>\n

Using a novel, Fc-free platform for integrating IL-15 signaling and TGF-\u03b2 neutralization, the Company has developed a T-Cell Engager Program focused on the treatment of solid tumors. HCW11-018b, the lead candidate of the \u201cBig BiTE\u201d program, is a multivalent T-cell engager designed to enhance anti-tumor activities and tolerability to treat a wide spectrum of solid tumors.<\/p>\n

HCW11-018b has a unique feature that has not been reported for any other T-Cell Engagers. In preclinical studies, HCW11-108b was shown to induce\/promote tertiary lymphoid structures (\u201cTLS\u201d) formation inside tumors. TLS are organized ectopic immune cell aggregates that form within non-lymphoid tissues \u2014 including solid tumors and the tumor microenvironment \u2014 in response to chronic inflammation. TLS are immune hubs in solid tumors that are clinically associated with more favorable outcomes following immunotherapy. Developing inside the tumor microenvironment, TLS locally train and expand killer T-cells (CD8+<\/sup>) and B-cells right where the threat exists, preventing immune exhaustion that can happen during immune cell transit from distant nodes.\u00a0\u00a0<\/p>\n

HCW11-018b incorporates the core features of a BiTE while adding components that alleviate immunosuppression and promote activation and tumor infiltration of cancer-fighting cells. The BiTE component of HCW11-018b contains an anti-CD3 single-chain antibody and an antibody domain that targets human Tissue Factor (\u201cTF\u201d), which is overexpressed in a wide spectrum of solid tumors. In addition, the molecule includes soluble IL-15, an IL-15 receptor \u03b1 (\u201cIL-15R\u03b1\u201d) domain, and a TGF-\u03b2 receptor II (\u201cTGF\u03b2RII\u201d) domain trap. The result is a compound that targets TF-positive tumor cells, engages CD3 on T cells, incorporates IL-15\/IL-15R\u03b1 activity, and uses a soluble TGF\u03b2RII domain as a TGF-\u03b2 trap to reduce immunosuppression. In preclinical studies, this structure has allowed HCW11-018b to turn \u201ccold\u201d tumors into \u201chot\u201d tumors by promoting infiltration of immune cells, in part by utilizing Cis-binding (or cis-interaction)\u00a0to enhance immune cell reactivity. In tumor efficacy models, HCW11-018b promotes targeted CD8+<\/sup> T cell killing of TF-positive tumor cells, inhibits growth of solid tumors, in some models leading to complete shrinkage of patient-derived pancreatic tumor implants, and reduces spread of tumor metastases.<\/p>\n

Communication with FDA at a recent Type B meeting provided the Company with clear guidance for the next steps to prepare its IND application to support a first-in-human clinical study to evaluate HCW11-018b in cancer, which the Company intends to do in the first half of 2027. In support of potential upcoming clinical trials, the Company has initiated cGMP manufacturing. HCW Biologics has created a high-expression production cell line and a streamlined GMP manufacturing process, utilizing a relatively simple manufacturing process similar to that used to make therapeutic monoclonal antibodies.<\/p>\n

Dr. Hing C. Wong, Founder and Chief Executive Officer, stated, \u201cThe SITC annual meeting provides us with the right venue to make this major update on our T-Cell Engager as a second-generation immunotherapy for cancer, giving us an opportunity to highlight the uniqueness and advantages of HCW11-018b. With our non-Fc based T-Cell Engager program derived from the TRBC platform, we have created a second-generation T-Cell Engager, HCW11-018b. HCW11-018b has demonstrated that the addition of TGF\u03b2-trap and IL-15 components onto a BiTE domain can overcome the deficiencies of BiTE alone for solid tumor therapy.\u201d<\/p>\n

Dr. Wong continued, \u201cThe feature of our lead T-Cell Engager candidate we recently discovered that it can promote tertiary lymphoid structure formation is unique and exciting. This distinctive feature of HCW11-018b and other TCEs that we built with our TRBC platform is highly differentiated from other BiTEs for solid tumor therapy.\u201d<\/p>\n

\n About HCW Biologics:<\/strong>\n <\/p>\n

HCW Biologics Inc. (the \u201cCompany\u201d) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. HCW Biologics is the leader in creation of multivalent immunotherapeutics with a unique protein-based scaffold, without antibody Fc domain. The Company\u2019s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation \u2014and in doing so, improve patients\u2019 quality of life and possibly extend longevity. A key aspect of the Company\u2019s clinical development and financing strategy is to focus on its business development programs, including its commercial-ready reagents to be used in the production of immunotherapeutics for cancer and infectious diseases. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https:\/\/hcwbiologics.com\/pipeline\/<\/a><\/p>\n

\n Forward Looking Statements:<\/strong>\n <\/p>\n

Statements in this press release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. These statements are made under the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201cforecast\u201d or other similar words and include, the actual success and potency of the Company\u2019s TCE-based TRBC fusion molecules; the ability of the Company\u2019s TCE\u2019s to target cancer antigens, activate effector T cells, promote infiltration of immune cells into tumors, shrink tumors, and reduce immunosuppression in the tumor microenvironment; the ability of the Company\u2019s TCEs to induce\/promote tertiary lymphoid structures (\u201cTLS\u201d) formation in tumors; the ability of the Company\u2019s TCEs to exhibit potent and antigen-specific anti-cancer activities both in vitro<\/em> and in humanized mouse models; effectiveness of the Company\u2019s TCEs in treatment of solid tumors; and the probability of receiving a favorable result from the submission of the IND for HCW11-018b based upon FDA Type B meeting response. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled \u201cRisk Factors\u201d in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the \u201cSEC\u201d) on March 31, 2026, and in other filings filed from time to time with the SEC.\u00a0\u00a0<\/p>\n

\n Company Contact:<\/strong>\n <\/p>\n

\n Dr. Peter Rhode<\/strong>
\n
Chief Scientific Officer and Vice President of Clinical Operations
HCW Biologics Inc.
PeterRhode@HCWBiologics.com<\/a>\u00a0<\/p>\n

This press release was published by a CLEAR\u00ae Verified individual.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HCW11-018b induces\/promotes tertiary lymphoid structure formation inside tumors HCW11-018b converts immunological \u201ccold\u201d tumors into \u201chot\u201d tumors HCW11-018b was generated using the Company\u2019s non-Fc TRBC platform, combining elements that enhance T-cell activation and tumor infiltration while mitigating immunosuppression MIRAMAR, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) — — HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and leading developer in novel multi-functional fusion immunotherapeutics, for the treatment of autoimmune diseases, cancer, and senescence-associated dysplasia, announced a major update for its multivalent, second-generation T-Cell Engager (\u201cTCE\u201d) Program, presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (\u201cSITC\u201d), taking place from November 4 \u2013 8, 2026, in Phoenix, Arizona. The Poster (Abstract #627), … <\/p>\n

Continue reading “HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018378","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HCW11-018b induces\/promotes tertiary lymphoid structure formation inside tumors HCW11-018b converts immunological \u201ccold\u201d tumors into \u201chot\u201d tumors HCW11-018b was generated using the Company\u2019s non-Fc TRBC platform, combining elements that enhance T-cell activation and tumor infiltration while mitigating immunosuppression MIRAMAR, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) — — HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and leading developer in novel multi-functional fusion immunotherapeutics, for the treatment of autoimmune diseases, cancer, and senescence-associated dysplasia, announced a major update for its multivalent, second-generation T-Cell Engager (\u201cTCE\u201d) Program, presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (\u201cSITC\u201d), taking place from November 4 \u2013 8, 2026, in Phoenix, Arizona. The Poster (Abstract #627), … Continue reading "HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T14:19:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting\",\"datePublished\":\"2026-11-06T14:19:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/\"},\"wordCount\":1266,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/\",\"name\":\"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg=\",\"datePublished\":\"2026-11-06T14:19:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/","og_locale":"en_US","og_type":"article","og_title":"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting - Market Newsdesk","og_description":"HCW11-018b induces\/promotes tertiary lymphoid structure formation inside tumors HCW11-018b converts immunological \u201ccold\u201d tumors into \u201chot\u201d tumors HCW11-018b was generated using the Company\u2019s non-Fc TRBC platform, combining elements that enhance T-cell activation and tumor infiltration while mitigating immunosuppression MIRAMAR, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) — — HCW Biologics Inc. (the \u201cCompany\u201d or \u201cHCW Biologics\u201d) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and leading developer in novel multi-functional fusion immunotherapeutics, for the treatment of autoimmune diseases, cancer, and senescence-associated dysplasia, announced a major update for its multivalent, second-generation T-Cell Engager (\u201cTCE\u201d) Program, presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (\u201cSITC\u201d), taking place from November 4 \u2013 8, 2026, in Phoenix, Arizona. The Poster (Abstract #627), … Continue reading \"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-06T14:19:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting","datePublished":"2026-11-06T14:19:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/"},"wordCount":1266,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/","name":"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg=","datePublished":"2026-11-06T14:19:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MTkxOSM3OTQ5OTkyIzIyMTAxOTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hcw-biologics-presents-newly-identified-distinctive-features-of-its-lead-t-cell-engager-candidate-built-with-companys-proprietary-t-cell-engager-platform-further-supporting-its-use-in-treati\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company\u2019s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer\u2019s 41st Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018378"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018378\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}